<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Yale J Biol Med</journal-id><journal-id journal-id-type="pmc">yjbm</journal-id><journal-title>The Yale Journal of Biology and Medicine</journal-title><issn pub-type="ppub">0044-0086</issn><issn pub-type="epub">1551-4056</issn><publisher><publisher-name>Yale Journal of Biology and Medicine</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">9825479</article-id><article-id pub-id-type="pmc">2589271</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>The relevance of somatostatin receptors in thyroid neoplasia.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ahlman</surname><given-names>H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Tisell</surname><given-names>L. E.</given-names></name></contrib><contrib contrib-type="author"><name><surname>W&#x000e4;ngberg</surname><given-names>B.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Fj&#x000e4;lling</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Forssell-Aronsson</surname><given-names>E.</given-names></name></contrib><contrib contrib-type="author"><name><surname>K&#x000f6;lby</surname><given-names>L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Nilsson</surname><given-names>O.</given-names></name></contrib></contrib-group><aff>Department of Surgery, Sahlgrenska University Hospital, G&#x000f6;teborg, Sweden.</aff><pub-date pub-type="ppub"><season>Sep-Dec</season><year>1997</year></pub-date><volume>70</volume><issue>5-6</issue><fpage>523</fpage><lpage>533</lpage><abstract><p>111In-octreotide scintigraphy in patients with persistent medullary thyroid carcinoma (MTC) visualized tumors in about half of the surgically explored sites. Tumor visualization correlated with rapid tumor growth and large tumor volume as judged from calcitonin levels. The 111In concentration ratio between tumor (T) and blood (B) in surgically excised lymph node metastases of MTC showed a large variation, with low values for microscopic and high values for macroscopic metastases in individual patients. Three cases of MTC, H&#x000fc;rthle cell adenoma and papillary thyroid cancer are reported with preoperative scintigraphy, T/B ratios and Northern analyses of the surgical biopsies. Visualization of tumors was possible in the absence of sstr2 (the high affinity receptor for octreotide) with the exception of microscopic tumor growth. T/B values in the patient with H&#x000fc;rthle cell adenoma were similar to those found in the contralateral thyroid lobe with goitre. The relatively high uptake of 111In in benign thyroid conditions probably limits the use of octreotide scintigraphy in the diagnosis of primary tumors. The technique has certain advantages over radioiodine scintigraphy after the surgical treatment of thyroid tumors: no need for withdrawal of thyroxin substitution; a possibility to diagnose metastases of tumors that do not concentrate radioiodine (MTC, H&#x000fc;rthle cell cancer); and complementary information about metastatic sites of non-medullary thyroid cancer (papillary and follicular tumors).</p><sec sec-type="scanned-figures"><title>Images</title><fig id="F1"><label>Figure 1</label><graphic xlink:href="yjbm00030-0061-a" xlink:role="526"/></fig><fig id="F2"><label>Figure 2</label><graphic xlink:href="yjbm00030-0063-a" xlink:role="528"/></fig><fig id="F3"><label>Figure 3</label><graphic xlink:href="yjbm00030-0064-a" xlink:role="529"/></fig><fig id="F4"><label>Figure 4</label><graphic xlink:href="yjbm00030-0065-a" xlink:role="530"/></fig></sec></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="yjbm00030-0058.tif" xlink:title="scanned-page" xlink:role="523" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="yjbm00030-0059.tif" xlink:title="scanned-page" xlink:role="524" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="yjbm00030-0060.tif" xlink:title="scanned-page" xlink:role="525" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="yjbm00030-0061.tif" xlink:title="scanned-page" xlink:role="526" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="yjbm00030-0062.tif" xlink:title="scanned-page" xlink:role="527" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="yjbm00030-0063.tif" xlink:title="scanned-page" xlink:role="528" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="yjbm00030-0064.tif" xlink:title="scanned-page" xlink:role="529" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="yjbm00030-0065.tif" xlink:title="scanned-page" xlink:role="530" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="yjbm00030-0066.tif" xlink:title="scanned-page" xlink:role="531" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="yjbm00030-0067.tif" xlink:title="scanned-page" xlink:role="532" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="yjbm00030-0068.tif" xlink:title="scanned-page" xlink:role="533" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

